20090264388 | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells - The present invention relates to neurokinin-1 (NK-1) receptor antagonists in combination with an inhibitor of metachromatic cell activation, such as an anti-inflammatory agent, an immunosuppressor, or a kinase inhibitor, and use of such combinations in the treatment of disorders associated with activation of metachromatic cells. Disorders associated with the activation of metachromatic cells include allergic/non-allergic rhinitis, allergic/non-allergic asthma, allergic/non-allergic urticaria, immuno-inflammatory disorders, metachromatic cell-related autoimmune disorders, transplant rejection, and other metachromatic cell-related disorders. | 10-22-2009 |